CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, Part 1: Overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal- Immune reconstitution inflammatory syndrome

American Journal of Neuroradiology

Volumn 34, Issue 7, 2013, Pages 1297-1307

  Post, M J D ^a   Thurnher, M M ^b   Clifford, D B ^c   Nath, A ^d   Gonzalez, R G ^e   Gupta, R K ^f   Post, K K ^g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^g UMass Memorial Medical Center University Campus ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CD8 ANTIGEN; CREATINE; D DIMER; FLUCONAZOLE; FLUCYTOSINE; INOSITOL; NATALIZUMAB; VIRUS RNA;

ANASTOMOSIS; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CONTRAST ENHANCEMENT; CROHN DISEASE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; CYTOTOXIC T LYMPHOCYTE; DIFFUSION WEIGHTED IMAGING; FRACTIONAL ANISOTROPY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL PRESSURE; JC VIRUS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM DISEASES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MENINGITIS, CRYPTOCOCCAL; NEUROIMAGING;

EID: 84880790953     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3183     Document Type: Review

References (99)

1. Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci 2010;1184:106-20.
2. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406.
3. Shelburne SA III, Hamill R. The immune reconstitution inflammatory syndrome. AIDS Reviews 2003;5:67-79.
4. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006;57:167-70.
5. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:251-61.
6. Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005;109:449-55.
7. Shelburne SA, III, Hamill RJ, Rodriquez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81:213-27.
8. Bonham S, Meya DB, Bohjanen PR, et al. Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med 2008;2:349-61.
9. Manabe Y, Campbell JD, Syndor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment applications. J Acquir Immune Defic Syndr 2007;46:456-62.
10. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE 2010;5:e11416.
11. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiret-roviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008;68:191-208.
12. French MA. Disorders of immune reconstitution in patients with HIVinfection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007;4:16-21.
13. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.
14. French MA. Immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009;48:101-07.
15. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-64.
16. Berkeley JL, Nath A, Pardo CA. Fatal immune reconstitution inflammatory syndrome with human immunodeficiency virus infection and Candida meningitis: case report and review of the literature. J Neurovirol 2008;14:267-76.
17. Navas E, Martin-Davilla P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Inn Med 2002;162:97-99.
18. Murdoch DM, Venter WDF, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007;4:1-10.
19. Riedel DJ, Pardo CA, McArthur J, et al. Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Prac Neurol 2006;2:557-65.
20. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009;51:130-34.
21. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009;72:835-41.
22. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006;67:383-88.
23. Gray F, Bazille C, Biassette-Adle H, et al. Central nervous system immunereconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005;11:16-22.
24. van der Ven AJ, van Oostenbrugge RJ, Kubat B, et al. Cerebral vasculitis after initiation antiretroviral therapy. AIDS 2002;16:2362-64.
25. Murdoch DM, Venter WDF, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008;22:601-10.
26. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infec Dis 2006;42:1639-46.
27. Stoll M, Schmidt RE. Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART. Curr HIV/AIDS Rep 2004;1:122-27.
28. Singer EJ, Sueiras-Valdes M, Commins D, et al. Neurologic presentations of AIDS. Neurol Clin 2010;28:253-75.
29. Sexton DJ, Pien BC, et al. Immune reconstitution inflammatory syndrome. UpToDate. Available at http://www.uptodate.com. Accessed January 31, 2012.
30. McCarthy M, Nath A. Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). Curr Neurol Neurosci Rep 2010;10:467-75.
31. McArthur JC, Steiner J, Sacktor N, et al. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699-714.
32. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54.
33. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992;6:1293-97.
34. Ohta K, Kishida S. Immune reconstitution inflammatory syndrome in the central nervous system. Brain Nerve 2007;59:1355-62.
35. Rushing EJ, Liappis A, Smirniotopoulos JD, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol 2008;67:819-27.
36. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 1998;54:19-33.
37. Navdeesh S, McCutchan JA. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J Neuroimmunol 2010;219:100-04.
38. Teo EC, Azwra A, Jones R, et al. Guillain-Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection. J HIV Ther 2007;12:62-63.
39. Anthony IC, Bell JE. Neuropathological findings associated with long-term HAART. In: Paul RH, Sacktor NC, Valcour V, et al, eds. HIV and the Brain: New Challenges in the Modern Era. New York: Humana Press; 2009:29-47.
40. Bazille GF, BiassetteMH, Moulignier A, et al. Central nervous system immunereconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005;3:16-22.
41. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006;42:418-27.
42. Huruy K, Andargachew M, Getahun M, et al.Immunereconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. J Infect Dis 2008;61:205-09.
43. Gray F, Chrétien F, Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003;62:429-40.
44. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002;16:2043-47.
45. Wang ME, Castillo ME, Silvia M, et al. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J 2009;28:900-03.
46. Kilborn T, Zampoli M. Immune reconstitution inflammatory syndrome after initiating highly active antiretroviral therapy in HIVinfected children. Pediatr Radiol 2009;39:569-74.
47. Major E. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
48. Hoffman C, Horst HA, Albrecht H, et al. Progressive multifocal leukoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003;74:1142-44.
49. Safdar A, Ruocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:1250-57.
50. Tantisiriwat W, Tebas P, Clifford DB, et al. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1998;28:1152-54.
51. Cinque P, Pierotti C, Vigano MG, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001;7:358-63.
52. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003;9:73-80.
53. Sidhu N, McCutchan JA. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J Neuroimmunol 2010;219: 100-04.
54. D'Amico R, Sarkar S, Yusuff J, et al. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis 2007;39:347-50.
55. Nuttall JJ, Wilmshurst JM, Ndondo AP, et al. Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis 2004;23:683-85.
56. Miller RF, Issacson PG, Hall-Craggs M, et al. Cerebral CD8 lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004;108:17-23.
57. Vidal JE, Penalva de Oliveira AC, Fink MC, et al. Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 2008;50:209-12.
58. Berger JR, Levy RM, Flomenhoft D, et al. Predictive factors for pro-longed survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341-49.
59. Cedeno-Laurent F, Penalva de Oliveira AC, Vidal JE, et al. Human polyomavirus-associated cerebral disorders in the post-HAART era. Patholog Res Int 2011;22:562427.
60. Wyen C, Hoffmann C, Schmeisser N, et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004;37:1263-68.
61. MarraCM, Rajicic N, Barker DE, et al, and the Adult AIDS Clinical Trials Group 363 Team. A pilot study of cidofovir for progressive multifocal leukoencephalopathy (PML) in AIDS. AIDS 2002;13:1791-97.
62. Post MJ, Yiannoutsos C. Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AJNR Am J Neuroradiol 1999;20:1896-906.
63. Berger JR, Kaszovitz B, Post MJ, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection; a review of the literature with a report of sixteen cases. Ann Intern Med 1987;107:78-87.
64. Berger JR Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009;1:583-89.
65. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999;52:623-25.
66. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999;5:421-29.
67. Bereenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003;36:1047-52.
68. Katz-Brull R, Lenkinski RE, Du Pasquier RA, et al. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 2004;63:897-900.
69. Cuvinciuc V, Martin-Blonde G, Marchou B, et al. Proton MR spectroscopy of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 2010;31:E69-E70.
70. Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997;48:836-45.
71. Thurnher MM, Post MJ, Rieger A, et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 2001;22:977-84.
72. Usiskin SI, Bainbridge A, Miller RF, et al. Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. AJNR Am J Neuroradiol 2007;28:285-86.
73. Bag AK, Cure JK, R, Chapman PR, et al. JC virus infection of the brain. AJNR Am J Neuroradiol 2010;31:1564-76.
74. Buckle C, Castillo M. Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience. AJNR Am J Neuroradiol 2010;31:1031-35.
75. Gheuens S, Bord E, Kesari S, et al. Role of CD4- and CD8- T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML-IRIS. J Virol 2011;85:7256-63.
76. Collazos J, Mayo J, Martinez E, et al. Contrast enhancing PML as an immunereconstitution event inAIDSpatients. AIDS 1999;13:1426-28.
77. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006;60:162-73.
78. Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993;187:233-40.
79. Giancola ML, Rizzi EB, Lorenzini P, et al. Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables. AIDS 2008;2:155-62.
80. Kotecha N, George MJ, Smith TW, et al. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998;105:541-43.
81. Berger JR. Steroids for PML-IRIS: a double-edged sword? Neurology 2009;72:1454-55.
82. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 2011;231:73-77.
83. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Neurology 2010;9:438-46.
84. Ransohoff RM. "Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007;259:50-52.
85. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
86. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
87. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005;353:414-16.
88. Tahir M, Sharma SK, Sinha S, et al. Immune reconstitution inflammatory syndrome in a patient with cryptococcal lymphadenitis as the first presentation of acquired immunodeficiency syndrome. J Postgrad Med 2007;53:250-52.
89. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1 infected individuals: literature review and proposed clinical case definition. Lancet Infect Dis 2010;10:781-802.
90. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PloS Med 2010;7:e1000384.
91. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2004;72:99-118.
92. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infec Dis 2009;49:-931-34.
93. Matthews VP, Alo PL, Glass JD, et al. AIDS-related CNS cryptococcosis: radiologic-pathologic correlation. AJNR Am J Neuroradiol 1992;13:1477-86.
94. King MD, Perlino CA, Cinnamon J, et al. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 2002;13:724-26.
95. Saigal G, Post MJ, Lolayekar S, et al. Unusual presentation of central nervous system cryptococcal infection in an immunocompetent patient. AJNR Am J Neuroradiol 2005;26:2522-26.
96. Cattelan AM, Trevenzoli M, Sasset L, et al. Multiple cerebral cryptococcomas associated with immune reconstitution in HIV-infection. AIDS 2004;18:49-51.
97. Saigal G, Post MJ, Kirwan R., et al. CNS cryptococcal infection: correlation of restricted diffusion and leptomeningeal enhancement with CSF cryptococcal antigen levels before and after medical therapy. In: Proceedings of the 44th Annual Meeting of the American Society of Neuroradiology, San Diego, California. May 6-12, 2006.
98. Lee YC, WangJT, Sun HY, et al. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2011;44:338-35.
99. Lu C-H, Chen H-L, Chang N-W, et al. Assessing the chronic neuropsychologic sequelae of human immunodeficiency virus-negative cryptococcal meningitis by using diffusion tensor imaging. AJNR Am J Neuroradiol 2011;32:1333-39.